Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells

E. Giovannetti; M. Labots; H. Dekker; E. Galvani; J.S.W. Lind; R. Sciarrillo; R.J. Honeywell; E.F. Smit; H.M. Verheul; G.J. Peters

doi:10.2174/138161213804547268

Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells

E. Giovannetti, M. Labots, H. Dekker, E. Galvani, J.S.W. Lind, R. Sciarrillo, R.J. Honeywell, E.F. Smit, H.M. Verheul, G.J. Peters

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	927-939
Journal	Current Pharmaceutical Design
Volume	19
Issue number	5
DOIs	https://doi.org/10.2174/138161213804547268
Publication status	Published - 2013

Access to Document

10.2174/138161213804547268

Cite this

Giovannetti, E., Labots, M., Dekker, H., Galvani, E., Lind, J. S. W., Sciarrillo, R., ... Peters, G. J. (2013). Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells. Current Pharmaceutical Design, 19(5), 927-939. https://doi.org/10.2174/138161213804547268

Giovannetti, E. ; Labots, M. ; Dekker, H. ; Galvani, E. ; Lind, J.S.W. ; Sciarrillo, R. ; Honeywell, R.J. ; Smit, E.F. ; Verheul, H.M. ; Peters, G.J. / Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells. In: Current Pharmaceutical Design. 2013 ; Vol. 19, No. 5. pp. 927-939.

@article{b3e7ddd5e0e649239af12408dd502cc4,

title = "Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells",

author = "E. Giovannetti and M. Labots and H. Dekker and E. Galvani and J.S.W. Lind and R. Sciarrillo and R.J. Honeywell and E.F. Smit and H.M. Verheul and G.J. Peters",

year = "2013",

doi = "10.2174/138161213804547268",

language = "Undefined/Unknown",

volume = "19",

pages = "927--939",

journal = "Current Pharmaceutical Design",

issn = "1381-6128",

publisher = "Bentham Science Publishers B.V.",

number = "5",

}

Giovannetti, E , Labots, M, Dekker, H, Galvani, E, Lind, JSW, Sciarrillo, R, Honeywell, RJ , Smit, EF , Verheul, HM & Peters, GJ 2013, 'Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells', Current Pharmaceutical Design, vol. 19, no. 5, pp. 927-939. https://doi.org/10.2174/138161213804547268

Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells. / Giovannetti, E.; Labots, M.; Dekker, H.; Galvani, E.; Lind, J.S.W.; Sciarrillo, R.; Honeywell, R.J.; Smit, E.F.; Verheul, H.M.; Peters, G.J.

In: Current Pharmaceutical Design, Vol. 19, No. 5, 2013, p. 927-939.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells

AU - Giovannetti, E.

AU - Labots, M.

AU - Dekker, H.

AU - Galvani, E.

AU - Lind, J.S.W.

AU - Sciarrillo, R.

AU - Honeywell, R.J.

AU - Smit, E.F.

AU - Verheul, H.M.

AU - Peters, G.J.

PY - 2013

Y1 - 2013

U2 - 10.2174/138161213804547268

DO - 10.2174/138161213804547268

M3 - Article

VL - 19

SP - 927

EP - 939

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 5

ER -